| Exclusion Criteria: | Pt may not be receiving any other investigational agents.
Pts with known brain mets should be excluded from this clinical trial because of poor prognosis & frequent development of progressive neurologic dysfunction, compounding evaluation & other adverse events.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Bevacizumab or other agents used in the study.
Tumor involvement of major vessels on CT scan, Hx of bleeding diathesis, CVA, PE or DVT, recent myocardial ischemia or infarction or uncompensated coronary artery disease within past 6 months, uncontrolled hypertension or sign. renal impairment.
Major surgery within prior 6 wks.
Currently active second malignancy other than non-melanoma skin or carcinoma in situ of the cervix. Pts with no evidence of recurrence for >/= 5 yrs are not considered to be "currently active."
Uncontrolled intercurrent illnesses that would limit compliance with study requirements.
Pregnant or nursing females.
HIV positive pts receiving combination anti-retroviral therapy.
Pts who have >/=1+ proteinuria at baseline must undergo 24 hr urine collection, which must demonstate <500 mg of protein/24 hrs to allow participation.
Pts w/recent (within 6mo) arterial thromboembolic events incl transient ischemic attach (TIA), cerebrovascular accident (CVA), unstable angina, or MI will be excluded. Pts w/clinically significant peripheral artery disease should also be excluded
|